Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Marinomed Biotech AG's share price for the quarter that ended in Dec. 2025 was €19.032982. Marinomed Biotech AG's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 1.85 Mil. Therefore, Marinomed Biotech AG's market cap for the quarter that ended in Dec. 2025 was €35.13 Mil.
Marinomed Biotech AG's quarterly market cap
increased
from Dec. 2024 (€26.68 Mil) to Jun. 2025 (€34.60 Mil) and
increased
from Jun. 2025 (€34.60 Mil) to Dec. 2025 (€35.13 Mil).
Marinomed Biotech AG's annual market cap
declined
from Dec. 2023 (€44.49 Mil) to Dec. 2024 (€26.68 Mil) but then
increased
from Dec. 2024 (€26.68 Mil) to Dec. 2025 (€35.13 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Marinomed Biotech AG's Enterprise Value for Today is €30.34 Mil.
Marinomed Biotech AG (WBO:MARI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Marinomed Biotech AG Market Cap Related Terms
Marinomed Biotech AG Market Cap Historical Data
* Premium members only.
The historical data trend for Marinomed Biotech AG's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:MARI vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Marinomed Biotech AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marinomed Biotech AG Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's Market Cap distribution charts can be found below:
* The bar in red indicates where Marinomed Biotech AG's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Marinomed Biotech AG's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marinomed Biotech AG (WBO:MARI) has a Market Cap of €19.89 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Marinomed Biotech AG and its competitors. According to the industry distribution chart, Marinomed Biotech AG ranks #1062 out of 1427 companies in the Biotechnology industry, placing it in the top 74.4%.
Is Marinomed Biotech AG's Market Cap too high?
Marinomed Biotech AG's current Market Cap is €19.89 Mil. Based on the distribution chart, Marinomed Biotech AG ranks #1062 out of 1427 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Marinomed Biotech AG has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marinomed Biotech AG ranks #1062 out of 1427 companies for Market Cap. This places Marinomed Biotech AG in the lower half of its industry. The industry median Market Cap is 119.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Marinomed Biotech AG and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marinomed Biotech AG's current Market Cap is €19.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (WBO:MARI) is currently considered Possible Value Trap. The stock's GF Value™ is €18.55, compared to a current price of €9.95 — trading 46.4% below its estimated fair value. The current Market Cap is €19.89 Mil. Marinomed Biotech AG's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Marinomed Biotech AG (WBO:MARI), the current Market Cap is €19.89 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?
Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued.
The current stock price of €9.95 is trading 46.4% below its estimated GF Value™ of €18.55.
GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.
Key valuation signals for WBO:MARI:
Market Cap: €19.89 Mil
GF Value™: €18.55 vs. price of €9.95 (46.4% below fair value)
No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
42GF Score
Get the complete analysis for WBO:MARI
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:MARI has been successfully added to your 
